WorkBoat Header Background Image

WorkBoat+ Membership – Free to Join

Limited Booth Space Remaining at IWBS. See the show floor layout and exhibit today. → Click Here

Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (NQ:QNTM)

3.910 +0.060 (+1.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 482,013
Open 3.830
Bid (Size) 3.970 (1,000)
Ask (Size) 4.050 (1,900)
Prev. Close 3.850
Today's Range 3.811 - 4.398
52wk Range 2.070 - 31.91
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Quest to Repair What Multiple Sclerosis Takes Away
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
Via Investor Brand Network

Performance

YTD
-44.2%
-44.2%
1 Month
-44.5%
-44.5%
3 Month
-10.1%
-10.1%
6 Month
-55.0%
-55.0%
1 Year
-85.6%
-85.6%

More News

Read More
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Featured in BioMedWire Editorial on Lucid-MS Program
Via Investor Brand Network
News headline image
Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach
From Quantum BioPharma Ltd.
Via GlobeNewswire
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Is ‘One to Watch’
Via Investor Brand Network
News headline image
The Quest to Repair What Multiple Sclerosis Takes Away
From BioMedWire
Via GlobeNewswire
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials
Via Investor Brand Network
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
Via Investor Brand Network
News headline image
Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis
From BioMedWire
Via GlobeNewswire
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Proprietary Therapy for Multiple Sclerosis Treatment
Via Investor Brand Network
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets
Via Investor Brand Network
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Engages Stocks.news for Investor Relations Services
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast
Via Investor Brand Network
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast
Via Investor Brand Network
News headline image
Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns
From Quantum BioPharma
Via GlobeNewswire
BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reports Midpoint Enrollment Milestone in Multiple Sclerosis Imaging Study
Via Investor Brand Network
News headline image
Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026
From Quantum BioPharma
Via GlobeNewswire
These stocks are moving in today's session ↗
Via Chartmill
News headline image
Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis
From Quantum BioPharma
Via GlobeNewswire
Friday's after hours session: top gainers and losers ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill

Frequently Asked Questions

Is Quantum Biopharma Ltd. - Class B Subordinate Voting Shares publicly traded?
Yes, Quantum Biopharma Ltd. - Class B Subordinate Voting Shares is publicly traded.
What exchange does Quantum Biopharma Ltd. - Class B Subordinate Voting Shares trade on?
Quantum Biopharma Ltd. - Class B Subordinate Voting Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Quantum Biopharma Ltd. - Class B Subordinate Voting Shares?
The ticker symbol for Quantum Biopharma Ltd. - Class B Subordinate Voting Shares is QNTM on the Nasdaq Stock Market
What is the current price of Quantum Biopharma Ltd. - Class B Subordinate Voting Shares?
The current price of Quantum Biopharma Ltd. - Class B Subordinate Voting Shares is 3.910
When was Quantum Biopharma Ltd. - Class B Subordinate Voting Shares last traded?
The last trade of Quantum Biopharma Ltd. - Class B Subordinate Voting Shares was at 06/24/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Privacy Policy DSAR Requests Terms of Use Locations Events, Products & Services
© 2026 Diversified Communications. All rights reserved.